Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...

Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a ...

Celltrion co-CEO Seo Jin-seok speaks during his presentation of the company's roadmap for new drugs at the 43rd J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

Rise in prevalence of ulcerative colitis and Crohn's disease, growing awareness of the disease across the world, drives the growth of the market David Correa Allied Market Research + 1 800-792-5285 ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...

To Know in detail about the Ulcerative Colitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ulcerative Colitis Market Forecast Some of the key facts of the ...

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...